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 Abstract 
 For more than half a decade, lithium has been successfully 
used to treat bipolar disorder. Worldwide, it is considered 
the first-line mood stabilizer. Apart from its proven antiman-
ic and prophylactic effects, considerable evidence also sug-
gests an antisuicidal effect in affective disorders. Lithium is 
also effectively used to augment antidepressant drugs in the 
treatment of refractory major depressive episodes and pre-
vent relapses in recurrent unipolar depression. In contrast to 
many psychiatric drugs, lithium has outlasted various phar-
macotherapeutic ‘fashions’, and remains an indispensable 
element in contemporary psychopharmacology. Neverthe-
less, data from pharmacogenetic studies of lithium are com-
paratively sparse, and these studies are generally character-
ized by small sample sizes and varying definitions of re-
sponse. Here, we present an international effort to elucidate 
the genetic underpinnings of lithium response in bipolar dis-
order. Following an initiative by the International Group for 
the Study of Lithium-Treated Patients (www.IGSLI.org) and 
the Unit on the Genetic Basis of Mood and Anxiety Disorders 
at the National Institute of Mental Health,  lithium research-
ers from around the world have formed the Consortium on 
Lithium Genetics (www.ConLiGen.org) to establish the larg-
est sample to date for genome-wide studies of lithium re-
sponse in bipolar disorder, currently comprising more than 
1,200 patients characterized for response to lithium treat-
ment. A stringent phenotype definition of response is one 
of the hallmarks of this collaboration. ConLiGen invites all 
lithium researchers to join its efforts. 
 Copyright © 2010 S. Karger AG, Basel 
 Background 
 The articles in this special issue of  Neuropsychobiology 
comprehensively review the use of lithium as a mood sta-
bilizer in bipolar and unipolar affective disorders. They 
show that 60 years after Cade’s discovery, lithium is still 
a first-line choice for prophylaxis in bipolar disorder. 
They furthermore discuss the evidence regarding lithi-
um’s antisuicidal effects, its use as an augmentation strat-
egy in the treatment of unipolar depression, and provide 
novel insights into its neurobiological mechanisms of ac-
tion. Finally, current pharmacogenetic knowledge about 
lithium treatment is reviewed. Taken together, however, 
these articles also highlight that, despite decades of lith-
ium use in psychiatry and despite the current emphasis 
on the study of psychiatric genetics in modern biological 
psychiatry, pharmacogenetic data regarding lithium 
treatment have a tendency to be circumstantial and in-
conclusive.
 Pharmacogenetics is a rapidly growing field that holds 
considerable promise for the development of medications 
that are more personalized and effective than those cur-
rently available. In all areas of medicine, pharmacoge-
netic studies of outcomes such as treatment response or 
characteristic side effects are on the rise; based on these 
findings, more and more pharmacogenetic tests are being 
offered and approved by the US Food and Drug Admin-
istration  [1] . Pretreatment genetic testing has now even 
been added to the prescribing information for the antico-
agulant warfarin  [2] . Similarly, the Food and Drug Ad-
ministration updated labeling for carbamazepine, rec-
ommending that patients of Asian ancestry be screened 
for the presence of the HLA allele B * 1502 that has been 
implicated in carbamazepine-induced Stevens-Johnson 
syndrome and toxic epidermal necrolysis in Han Chinese 
people  [3] .
 Sufficiently large, well-characterized samples as well 
as effective and efficient collaboration between academia 
and the pharmaceutical industry are among the critical 
prerequisites for success in the field of pharmacogenetics 
 [4, 5] . Pharmacogenetic research in psychiatry has long 
been characterized by single lab efforts and small sample 
sizes. Only recently has our field witnessed large collab-
orative studies such as the Sequenced Treatment Alterna-
tives to Relieve Depression (STAR * D) study (http://www.
edc.pitt.edu/stard/)  [6] in the United States, or the Ge-
nome-Based Therapeutic Drugs for Depression (GEN-
DEP) project (http://gendep.iop.kcl.ac.uk)  [7] in Europe, 
both of which study the pharmacogenetics of major de-
pression. Indeed, the STAR * D and GENDEP projects 
have already generated several intriguing findings con-
cerning the genetics of treatment response and side ef-
fects  [8–14] . It is hoped that genome-wide asso ciation 
studies (GWAS) conducted in these and other samples 
will significantly increase our ability to guide the phar-
macological treatment of psychiatric patients through 
the identification of genetic markers.
 Notably, despite lithium’s proven efficacy  [15] , to date 
there has been only one GWAS examining this ‘pharma-
cological workhorse’ of psychiatry  [16] . In two cohorts 
encompassing more than 800 lithium-treated patients, 
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multiple regions of interest were identified but none met 
the threshold for genome-wide significance. While in-
triguing, no adequately powered cohort yet exists to rep-
licate and extend these findings. Here, we present a world-
wide effort to address this situation: the international 
Consortium on Lithium Genetics (ConLiGen), spear-
headed by researchers from the International Group for 
the Study of Lithium-Treated Patients (IGSLI) and the 
National Institute of Mental Health (NIMH).
 The International Group for the Study of
Lithium-Treated Patients 
 The IGSLI is an international group of scientists dedi-
cated to lithium-related research, and its use in mental 
illness and mood disorders in particular. Founded in 
1988 by Mogens Schou (Risskov/Aarhus, Denmark), Bru-
no Müller-Oerlinghausen (Berlin, Germany), and Paul 
Grof (Ottawa, Canada), the IGSLI has significantly con-
tributed to lithium research over the past 20 years (www.
igsli.org). Other scientists and centers have since joined 
the group, which currently comprises 35 members from 
Austria, Canada, the Czech Republic, Denmark, Germa-
ny, Poland, Switzerland, and the United States. The main 
goal of this group has been to conduct systematic work 
on those key questions regarding lithium treatment that 
can only be resolved by joint international effort. Unified 
designs have been created and scientific data from the 
IGSLI member centers have been linked for the purpose 
of shared analysis. This approach allows investigators to 
work with large numbers of prospectively followed pa-
tients – something that could only be accomplished via a 
multicenter approach. Overall, IGSLI research is based 
on shared, standardized, computer-based documenta-
tion of patients’ diagnoses, family histories, course of ill-
ness before and during treatment, and on comparable 
modalities of treatment. The group meets regularly at re-
search conferences to plan and discuss joint projects and 
to prepare publications.
 At the 21st IGSLI meeting, which took place in late 
September 2007 in Dresden, Germany, the group dis-
cussed the results from the first, newly released GWAS of 
bipolar disorder, performed by researchers from the 
NIMH and Germany  [17] . The strongest findings identi-
fied and replicated in this study were those encoding dia-
cylglycerol kinase eta, a key protein in the lithium-sensi-
tive phosphatidylinositol pathway and several genes in 
the  Wnt -signaling cascade. Given the absence of a hy-
pothesis-driven selection of single nucleotide polymor-
phisms in GWAS – a method more typical of candidate 
gene association studies – the observation that these find-
ings implicated pathways relevant to lithium’s mecha-
nism of action was particularly intriguing. Spurred on by 
these findings, the IGSLI researchers concluded that 
studying these genes in samples that included data on pa-
tient response to lithium treatment could improve our 
understanding of how these genes determine response to 
lithium treatment and impact susceptibility to bipolar 
disorder. The IGSLI  collaborators thus agreed to explore 
a framework that would allow researchers to engage in 
genetic studies of lithium response that were sufficiently 
powered. It was stated that such an endeavor should allow 
for participation by all bona fide lithium researchers 
within and beyond the IGSLI, while maintaining the 
highest possible level of stringency regarding phenotype 
definition.
 May 6, 2008:
The Consortium on Lithium Genetics Is Born 
 Following an invitation by IGSLI member Thomas G. 
Schulze and Francis J. McMahon, both from the NIMH’s 
Unit on the Genetic Basis of Mood and Anxiety Disor-
ders, prominent scientists in the field of lithium and bi-
polar genetic research met at the NIMH to discuss the 
possibility of creating an international consortium dedi-
cated to the study of lithium pharmacogenetics. In atten-
dance were (in alphabetical order): Martin Alda (Halifax, 
N.S., Canada), Michael Bauer (Dresden, Germany), Ma-
ria Del Zompo (via phone from Cagliari, Italy), Gonzalo 
Laje (Bethesda, Md., USA), Francis J. McMahon (Bethes-
da, Md., USA), Mirko Manchia (Cagliari, Italy), Roy
H. Perlis (Boston, Mass., USA), Janusz K. Rybakowski 
(Poznan, Poland), Thomas G. Schulze (Bethesda, Md., 
USA), Johannes Schumacher (Bethesda, Md., USA), and 
Jordan W. Smoller (Boston, Mass., USA).
 Reviewing evidence from the literature, and based on 
their own observations, the group emphasized the evi-
dent familiality in lithium treatment response, raising 
the possibility that genetic variation may contribute to 
interindividual differences in treatment response. If such 
differences could be identified, they might facilitate the 
development of novel treatments for bipolar disorder, or 
allow for better matching between patients and treat-
ments. Over the last decade, the quest for a ‘personalized 
medicine’ approach in psychiatry has propelled a host of 
pharmacogenetic studies. Because of the lengthy trial-
and-error process that currently characterizes the search 
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for the most optimal treatment, pharmacogenetic studies 
in psychiatry have traditionally focused on treatment re-
sponse or adverse effects associated with antidepressants 
or antipsychotic medications  [18–22] . While initially lim-
ited by small sample sizes, pharmacogenetic studies in 
psychiatry have increasingly come to rely on large-scale 
collaborative efforts, such as STAR * D, GENDEP, or
the Clinical Antipsychotic Trials of Intervention Effec-
tiveness (CATIE) project. While some pharmacogenetic 
studies performed with these collaborative samples have 
produced intriguing results, difficulties in defining strin-
gent target phenotypes across the various subsamples re-
main an important challenge  [23, 24] .
 The researchers gathered at the NIMH on May 6, 2008 
noted that, despite considerable and well-documented 
worldwide experience with lithium as an effective anti-
manic agent, mood stabilizer, and putative antisuicidal 
agent, there is a surprising dearth of large-scale pharma-
cogenetic studies of lithium treatment. We thus decided 
to create an international initiative whose goal would be 
to facilitate high-quality, well-powered analyses of lithi-
um treatment response data that would ultimately allow 
for robust conclusions. The Consortium on Lithium Ge-
netics, hereafter referred to as ConLiGen, was born.
 ConLiGen’s Scientific Goals 
 ConLiGen aims to identify genetic determinants of re-
sponse to lithium treatment in bipolar disorder, as well as 
genetic determinants of adverse events emerging during 
lithium treatment. In the long run, ConLiGen may also 
study response to lithium treatment in general (e.g. lith-
ium augmentation in the treatment of major depres-
sion).
 Membership in ConLiGen 
 Any bona fide researcher or research group with ac-
cess to samples of lithium-treated patients for whom 
DNA is available can join ConLiGen. Any new admission 
request is voted upon by ConLiGen members. 
 Communication between the ConLiGen Members 
 To ensure a constant exchange of ideas between mem-
bers and allow for a straightforward realization of Con-
LiGen’s goals, a monthly conference call is conducted. 
Furthermore, members meet once or twice a year at in-
ternational meetings of various biological psychiatric or-
ganizations.
 ConLiGen Advisory Board 
 An Advisory Board comprising international experts 
in the field of mood disorders research, and lithium re-
search in particular, was established to offer ConLiGen 
an outside perspective as well as guidance on broad sci-
entific directions,  to serve as a liaison to nonacademic 
communities such as funding institutions, or industry, 
and finally, to act as one of ConLiGen’s publicly visible 
faces. Currently, the following researchers are members 
of the Advisory Board (in alphabetical order): Robert H. 
Belmaker (Division of Psychiatry, Ben Gurion University 
of the Negev, Beersheva, Israel), Gian Luigi Gessa (De-
partment of Neuroscience ‘B.B. Brodie’, University of Ca-
gliari, Cagliari, Italy), Paul Greengard (Laboratory of 
Molecular and Cellular Neuroscience, Rockefeller Uni-
versity, New York, N.Y., USA), Kay R. Jamison (Depart-
ment of Psychiatry and Behavioral Sciences, Johns Hop-
kins University School of Medicine, Baltimore, Md., 
USA), Richard S. Jope (Department of Psychiatry and 
 Behavioral Neurobiology, University of Alabama at 
 Birmingham, Birmingham, Ala., USA), Husseini K. 
Manji (CNS & Pain, Johnson and Johnson Pharmaceuti-
cal Research and Development, Titusville, N.J., USA), 
and Leon E. Rosenberg (Department of Molecular Biol-
ogy and the Woodrow Wilson School of Public and In-
ternational Affairs, Princeton University, Princeton, N.J., 
USA).
 Phenotype Definition of Lithium Response:
A Major Prerequisite for Pharmacogenetic Studies 
of Lithium 
 ConLiGen’s first and most crucial goal is to define the 
phenotype of lithium response. Treatment response is a 
complex construct that requires researchers to make 
judgments about adequacy of treatment and tolerability 
as well as assess changes in episode frequency or symp-
tom severity. In many cases this information must be as-
sessed retrospectively, with the inherent limitations as-
sociated with recall bias, missing information, or the fact 
that the treatment has not followed a strict research pro-
tocol. One scale that incorporates such data is an 11-point 
scale developed by Martin Alda and colleagues  [25] 
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( fig. 1 ); other approaches include longitudinal outcome 
measures that consider time to recurrence or symptom 
burden during treatment  [16, 26] .
 The 11-point scale measures the extent of improve-
ment during long-term treatment. The scale’s A score is 
a composite measure of change in frequency, duration, 
and severity of illness episodes in the course of lithium 
treatment. It is weighted by factors that influence the 
degree to which the observed clinical change is consid-
ered to be due to lithium (B1–B5 scores in the scale). The 
scale has been developed in the context of a study assess-
ing response to treatment in subjects not followed ac-
cording to a research protocol, namely relatives of pro-
bands in our genetic studies  [25] . Subsequently, it has 
been widely used in several other studies at IGSLI cen-
ters  [27–29] and at other centers involved in lithium re-
search [pers. commun. from John Kelsoe, San Diego, 
Calif., USA and Maria del Zompo, Cagliari, Italy], which 
imparts face validity. Within ConLiGen, phenotypic as-
sessment will be based on any available information in-
© Martin Alda, 2002 
 
Name: _______________________Date: ________________ 
 
Criterion A 
 
The criterion A is used to determine an association between clinical 
improvement and the treatment. The rating should apply to the period 
of treatment considered adequate in duration and dosage. The illness 
activity should be judged by frequency, severity, and duration of 
episodes. 
 
10 = Complete response, no recurrences in the course of adequate 
treatment, no residual symptoms, and full functional recovery 
9 = Very good response, no recurrences, but the patient may have 
minimal residual symptoms (transient anxiety, sleep disturbance, 
dysphoria, irritability) not requiring any intervention 
8 = Very good response. Illness activity reduced by more than 90% 
7 = Good response. Illness activity reduced by 80 - 90 % 
6 = Good response. Reduction in activity of illness by 65 - 80% 
5 = Moderate response. Reduction in illness activity by 50 - 65% 
4 = Moderate improvement. Reduction in illness activity by 35 - 50% 
3 = Mild improvement. Reduction of illness activity by 20 - 35% 
2 = Mild improvement. Reduction of illness activity by 10 - 20% 
1 = Minimal improvement. Reduction of illness activity by 0 - 10% 
0 = No change or worsening 
 
                                                     A Criterion Score:  _______ 
 
 
Criteria B 
 
The criteria B are used to establish whether there is a causal 
relationship between clinical improvement and the treatment. Score 0, 
1 or 2 points for each item: 
 
B1: Number of episodes off the treatment. 
 
0 = 4 or more episodes 
1 = 2 or 3 episodes 
2 = 1 episode 
 
B1: _____ 
  
 
 
 
 
 
 
 
Drug: ______________Evaluated By: ___________ 
 
B2: Frequency of episodes off the treatment. 
 
0 = Average to high, including rapid cycling 
1 = Low, spontaneous remissions of 3 or more years on average 
2 = 1 episode only, risk of recurrence cannot be established                   
 
B2: _____ 
 
B3: Duration of the treatment.  
 
0 = 2 or more years 
1 = 1 - 2 years 
2 = Less than 1 year 
 
B3: _____ 
 
B4: Compliance during period(s) of stability. 
 
0 = Excellent, e.g. documented by drug levels in the therapeutic 
   range 
1 = Good, more than 80% levels in the therapeutic range 
2  = Poor, repeatedly off treatment, less than 80% levels in the 
   therapeutic range 
 
B4: _____ 
 
B5: Use of additional medication during the period of stability. 
 
0 = None except infrequent sleep medication (1 per week or less); 
   no other mood stabilizers, antidepressants or antipsychotics for 
   control of mood symptoms 
1 = Low-dose antidepressants or antipsychotics as an "insurance", 
   or prolonged use of sleep medication 
2 = Prolonged or systematic use of an antidepressant or  
 antipsychotic 
 
B5: _____ 
 
 
B Criteria Score:   _____ 
 
 
Total Scale Score:  _____ 
(Subtract B from A) 
Fig. 1. Retrospective criteria of long-term treatment response in research subjects with bipolar disorder.
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cluding life charts when available and quantified using 
the scale; interrater reliability meetings will be orga-
nized, facilitated by ConLiGen member Martin Alda, 
and case vignettes will also be reviewed to establish be-
tween-center reliability.
 Variables describing treatment tolerability or side ef-
fects may be studied in subsequent projects. Because the 
issue of ‘best response phenotype’ is far from trivial, Con-
LiGen will strive to continuously weigh evidence from 
future clinical and biological studies of lithium in an ef-
fort to refine the definition of phenotype response. Eval-
uating response to long-term treatment in an illness with 
a highly variable natural course presents a challenge. 
Many patients with bipolar disorder experience sponta-
neous remissions of variable timing and duration. More-
over, in a pharmacogenetic study we need to evaluate the 
quality of response not for groups of subjects as in clinical 
trials but individually for each patient. While prospective 
studies will be able to implement more precise measures, 
our approach is a practical way to assess the quality of 
response in a variety of patients treated in diverse set-
tings.
 ConLiGen’s Current Project and Long-Term Mission 
 ConLiGen is poised to assess all aspects of the phar-
macogenetics of lithium treatment in psychiatric disor-
ders, including the study of genetic susceptibility to po-
tential treatment-emergent adverse events (e.g. weight 
gain, hypothyroidism, tremor). As its first project, Con-
LiGen intends to conduct a GWAS of stringently defined 
response to lithium treatment in bipolar disorder. Con-
LiGen members and the various research centers which 
they are affiliated with are joining their samples for a 
centralized genotyping effort to be performed at the 
Unit on the Genetic Basis of Mood and Anxiety Disor-
ders of the NIMH and the Department of Genomics of 
the Life and Brain Center at the University of Bonn, Ger-
many. For the primary projects, a previously validated 
scale will be used to define response to lithium treat-
ment, as described above. Individuals scoring between 
7 and 10 will be considered lithium ‘responders’, while 
individuals with scores between 0 and 6 will be consid-
ered ‘nonresponders’. Presently, the total sample com-
prises more than 1,200 bipolar patients for whom re-
sponse to lithium treatment has been or is currently be-
ing assessed by means of the scale. From preliminary 
analyses conducted in select IGSLI samples (data not 
shown), we can assume that about 35–40% of patients 
will qualify as responders. Previous studies  [8, 9] sug-
gest larger genetic effect sizes (e.g. allelic odds ratios be-
tween 1.5 and 2) for a narrowly defined pharmacoge-
netic phenotype than for a categorically defined clinical 
diagnosis. Thus, assuming a minor allele frequency of 
0.3 and genotype relative risks of 1.4 for individuals het-
erozygous, and of 1.96 for individuals homozygous for 
the risk allele, the combined ConLiGen sample will have 
a power of 83% to detect an effect at a significance level 
of 1  ! 10 –8  [30] .
 Although the combined ConLiGen sample will be the 
largest sample to date to investigate lithium response on 
a genome-wide scale, we are aware that any finding, re-
gardless of whether it reaches levels of genome-wide sig-
nificance, will ultimately have to be confirmed in inde-
pendent samples. Thus, ConLiGen’s mission will not be 
finished after the completion of its GWAS. On the con-
trary, ConLiGen  will continue to invite researchers to 
join its efforts in order to increase the available sample 
size of patients adequately characterized for lithium re-
sponse. In collaboration with both IGSLI centers and 
large, long-standing multicenter projects such as the 
NIMH Bipolar Disorder Genetics Initiative, ConLiGen 
will be actively engaged in supporting and organizing ur-
gently needed prospective studies of lithium response in 
bipolar disorder and other conditions.
 Since Cade discovered lithium’s beneficial effects in 
the treatment of bipolar disorder 60 years ago, this agent 
has become almost synonymous with the treatment of 
bipolar disorder worldwide  [15] . Yet, little is known about 
the genetic underpinnings of lithium response or the de-
velopment of side effects associated with its use. In a sci-
entific environment characterized by calls for personal-
ized medicine and the growth of large-scale pharmaco-
genetic studies in many fields of medicine, ConLiGen’s 
goal is to put lithium at the forefront of pharmacogenetic 
studies in psychiatry.
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